|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...90919293949596979899100...110111» |
- Triapine (3-AP) / Vion, Northwestern University
Enrollment change, Combination therapy, Metastases: Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies (clinicaltrials.gov) - Jan 9, 2013
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=11 --> 24
- | New P2 trial: A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes (clinicaltrials.gov) - Jan 8, 2013
P2, N=25, Recruiting, Sponsor: Devirex AG
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial termination: Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 8, 2013
P1, N=48, Terminated, Sponsor: National Cancer Institute (NCI)
N=11 --> 24 Active, not recruiting --> Terminated
- | Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer (clinicaltrials.gov) - Jan 8, 2013
P2, N=15, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Terminated N=31 --> 15
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Enrollment change, Metastases: A Study of Trabectedin in Patients With Advanced Ovarian Cancer (clinicaltrials.gov) - Jan 8, 2013
P2, N=147, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=31 --> 15 N=37 --> 147
- HEOR: Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (clinicaltrials.gov) - Jan 8, 2013
P=N/A, N=48, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
- | New P2 trial: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Jan 8, 2013
P2, N=60, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
- | Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer (clinicaltrials.gov) - Jan 8, 2013
P2, N=15, Completed, Sponsor: The Cleveland Clinic
N=37 --> 147 Active, not recruiting --> Completed
- Clinical: Prediction of Clinical Response and Outcome in Uterine Cervix Cancer (clinicaltrials.gov) - Jan 7, 2013
P=N/A, N=100, Recruiting, Sponsor: Maastricht Radiation Oncology
- |||||| Entereg (alvimopan) / Merck (MSD)
Enrollment open, Surgery: Accelerating Gastrointestinal Recovery (clinicaltrials.gov) - Jan 7, 2013
P3, N=134, Recruiting, Sponsor: Jamie N. Bakkum-Gamez
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- medroxyprogesterone / Generic mfg.
Enrollment change: Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD) (clinicaltrials.gov) - Jan 6, 2013
P1/2, N=0, Withdrawn, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Recruiting N=56 --> 0
- New P1/2 trial: GoldenCareTM for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Jan 6, 2013
P1/2, N=8, Terminated, Sponsor: CDA Research Group, Inc.
- Trial completion, Metastases: IMSIAMA: Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age (clinicaltrials.gov) - Jan 6, 2013
P=N/A, N=66, Completed, Sponsor: Sapientiae Institute
N=56 --> 0 Recruiting --> Completed
- |||||| Zorbtive (somatropin) / EMD Serono
Enrollment open: Growth Hormone in Poor Responders to IVF Trial (clinicaltrials.gov) - Jan 6, 2013
P2/3, N=60, Recruiting, Sponsor: Pacific Centre for Reproductive Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial termination, Combination therapy: E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 (clinicaltrials.gov) - Jan 1, 2013
P1/2, N=7, Terminated, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; poor accrual
- |||| carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Combination therapy: Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer (clinicaltrials.gov) - Dec 30, 2012
P2, N=150, Completed, Sponsor: Duke University
Active, not recruiting --> Terminated; poor accrual N=250 --> 150 | Recruiting --> Completed
- |||| carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy: Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer (clinicaltrials.gov) - Dec 30, 2012
P2, N=150, Completed, Sponsor: Duke University
N=250 --> 150 | Recruiting --> Completed Recruiting --> Completed
- Preclinical: Clinical Measures of Ovarian Reserve in Predicting IVF Success (clinicaltrials.gov) - Dec 26, 2012
P=N/A, N=300, Enrolling by invitation, Sponsor: University of Oxford
- carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Enrollment change, Combination therapy, Metastases: PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer (clinicaltrials.gov) - Dec 26, 2012
P1, N=11, Completed, Sponsor: AA Secord
Recruiting --> Completed N=24 --> 11
- ethinyl estradiol/levonorgestrel / Generic mfg.
New P4 trial: Pituitary Down-regulation Before IVF for Women With Endometriosis (clinicaltrials.gov) - Dec 26, 2012
P4, N=5, Terminated, Sponsor: University of Oxford
- carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Trial completion, Combination therapy, Metastases: PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer (clinicaltrials.gov) - Dec 26, 2012
P1, N=11, Completed, Sponsor: AA Secord
N=24 --> 11 Active, not recruiting --> Completed
- Trial withdrawal: PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=0, Withdrawn, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=0, Withdrawn, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Withdrawn N=30 --> 0
- topotecan / Generic mfg., erlotinib / Generic mfg.
Trial termination: Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer (clinicaltrials.gov) - Dec 23, 2012
P2, N=6, Terminated, Sponsor: New York University School of Medicine
N=30 --> 0 Active, not recruiting --> Terminated; due to administrative issue and financial sponsor decision to suspend ovarian cancer studies
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial initiation date: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Dec 20, 2012
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
Active, not recruiting --> Terminated; due to administrative issue and financial sponsor decision to suspend ovarian cancer studies Initiation date: Apr 2011 --> Dec 2011
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Dec 20, 2012
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
Initiation date: Apr 2011 --> Dec 2011 N=15 --> 9
- ||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial initiation date: Ovarian Cancer Vaccine for Patients in Remission (clinicaltrials.gov) - Dec 20, 2012
P2b, N=63, Active, not recruiting, Sponsor: Prima BioMed Ltd
N=15 --> 9 Initiation date: Feb 2010 --> Jun 2010
- | candida vaccine (PEV7) / Pevion
Trial completion: Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection (clinicaltrials.gov) - Dec 20, 2012
P1, N=48, Completed, Sponsor: Pevion Biotech Ltd
Initiation date: Feb 2010 --> Jun 2010 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Dec 20, 2012
P2, N=35, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, IO biomarker: Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (clinicaltrials.gov) - Dec 20, 2012
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- Enrollment open: Use of GM-CSF Supplemented IVF Medium in Patients With Recurrent Implantation Failure (clinicaltrials.gov) - Dec 19, 2012
P4, N=100, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Suspended --> Completed Not yet recruiting --> Recruiting
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) (clinicaltrials.gov) - Dec 19, 2012
P3, N=80, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- epinephrine / Generic mfg.
Trial completion: Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs) (clinicaltrials.gov) - Dec 19, 2012
P2, N=55, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial withdrawal: Photoacoustic Endoscopy in Endometrial Cancer (clinicaltrials.gov) - Dec 19, 2012
P0, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Photoacoustic Endoscopy in Endometrial Cancer (clinicaltrials.gov) - Dec 19, 2012
P0, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Not yet recruiting --> Withdrawn N=20 --> 0
- Avastin (bevacizumab) / Roche
Trial completion: Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma (clinicaltrials.gov) - Dec 19, 2012
P2, N=38, Completed, Sponsor: Washington University School of Medicine
N=20 --> 0 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion: Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer (clinicaltrials.gov) - Dec 19, 2012
P2, N=27, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Outcomes of Delivery in Patients With Dyspareunia (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=200, Not yet recruiting, Sponsor: Hadassah Medical Organization
- Trial completion: CoPPer Study - Complications of Polycystic Ovary Syndrome (PCOS) Pregnancy: Evaluating Risk (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=300, Completed, Sponsor: UMC Utrecht
Active, not recruiting --> Completed Recruiting --> Completed
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion: Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids (clinicaltrials.gov) - Dec 17, 2012
P2a, N=30, Completed, Sponsor: BioPro Medical Ltd
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2) (clinicaltrials.gov) - Dec 16, 2012
P1/2, N=12, Active, not recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Completed N=15 --> 12
- Enrollment closed: Chinese Cancer Prevention Study(CHICAPS) (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=10000, Active, not recruiting, Sponsor: Preventive Oncology International, Inc.
N=15 --> 12 Recruiting --> Active, not recruiting
- Triapine (3-AP) / Vion, Northwestern University
Trial completion, Combination therapy: Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer (clinicaltrials.gov) - Dec 16, 2012
P2, N=28, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Hepacid (pegargiminase) / Polaris Pharma
Enrollment open, Metastases: Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma (clinicaltrials.gov) - Dec 15, 2012
P1, N=89, Recruiting, Sponsor: Polaris Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion, Preclinical, Head-to-Head: Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH) (clinicaltrials.gov) - Dec 13, 2012
P=N/A, N=30, Completed, Sponsor: University Hospital Tuebingen
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- cisplatin / Generic mfg.
Trial termination, Metastases: Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer (clinicaltrials.gov) - Dec 13, 2012
P3, N=101, Terminated, Sponsor: Mark Dewhirst
Not yet recruiting --> Completed Active, not recruiting --> Terminated; Study was closed because of slow accrual
- Trial termination: LLLT: Low Level Laser Therapy for the Treatment of Provoked Vestibulodynia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=34, Terminated, Sponsor: Hadassah Medical Organization
Active, not recruiting --> Terminated; Study was closed because of slow accrual Recruiting --> Terminated
- Follistim AQ Cartridge (follitropin beta) / Organon
Trial suspension, Head-to-Head: CLOVANT: RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders (clinicaltrials.gov) - Dec 12, 2012
P4, N=106, Suspended, Sponsor: Weill Medical College of Cornell University
Recruiting --> Terminated Recruiting --> Suspended
- Enrollment change: LLLT: Low Level Laser Therapy for the Treatment of Provoked Vestibulodynia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=34, Terminated, Sponsor: Hadassah Medical Organization
Recruiting --> Suspended N=80 --> 34
- Enrollment closed: Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Dec 12, 2012
P3, N=45, Active, not recruiting, Sponsor: Rogerio A. Lobo
N=80 --> 34 Recruiting --> Active, not recruiting